131895-07-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-bromophenyl)-3-methylbutan-1-one is used as a key intermediate for the synthesis of various pharmaceuticals. Its aromatic properties and unique structure make it a valuable building block for creating biologically active compounds, contributing to the development of new drugs and therapies.
Used in Perfumery Industry:
1-(4-bromophenyl)-3-methylbutan-1-one is used as a fragrance ingredient in the perfumery industry. Its aromatic properties allow it to contribute to the creation of unique and complex scents, enhancing the overall appeal and quality of perfumes and fragrances.
Organic Synthesis:
1-(4-bromophenyl)-3-methylbutan-1-one is used as a versatile building block in organic synthesis. Its unique structure and functional groups enable chemists to create a wide range of compounds for various applications, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Pharmaceutical Research:
1-(4-bromophenyl)-3-methylbutan-1-one is used in pharmaceutical research as a starting material for the development of new drugs. Its structural diversity and reactivity make it an ideal candidate for exploring novel therapeutic agents and advancing the field of medicinal chemistry.

Upstream product

• 26464-05-1 2-bromo-3-methyl-butyryl bromide 
• 108-86-1 bromobenzene 
• 108-12-3 isopentanoyl chloride 
• 623-00-7 4-bromobenzenecarbonitrile 
• 926-62-5 isobutylmagnesium bromide 
• 55991-66-7 1-(4-bromophenyl)-1-(trimethylsilyloxy)ethylene 
• 586-76-5 4-Bromobenzoic acid 
• 847453-58-1 2-bromo-1-(4-bromophenyl)-3-methylbutan-1-one 
• 5674-02-2 2-methylpropylmagnesium chloride 
• 192436-83-2 4-bromo-N-methoxy-N-methylbenzamide 

Downstream Products

• 91428-21-6 p-BrC₆H₄CH(iso-C₄H₉)NH₂ 
• 847453-58-1 2-bromo-1-(4-bromophenyl)-3-methylbutan-1-one 
• 121198-77-4 4'-aminoisovalerophenone 

Relevant academic research and scientific papers

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

Photoredox Reaction of 2-Mercaptothiazolinium Salts with Silyl Enol Ethers

A method for the generation of free radicals from thiazolinium salts upon photocatalytic reduction is described. The thiazolinium salts are generated by treatment with methyl triflate of 2-mercaptothiazolines, which can be readily obtained from alkyl bromides and tosylates via a nucleophilic substitution reaction or by hydrothiolation of alkenes. Silyl enol ethers were used to trap the radicals, furnishing ketones after successive single-electron oxidation and elimination of the silyl cation.

DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS

Compounds of formula (I) which are nicotinamide phosphoribosyltransferase (NAMPT) inhibitors and their use for the treatment of hyperproloferative diseases and/or disorders responsive to induction of cell death.

Synthesis and methemoglobinemia-inducing properties of analogues of para-aminopropiophenone designed as humane rodenticides

A number of structural analogues of the known toxicant para- aminopropiophenone (PAPP) have been prepared and evaluated for their capacity to induce methemoglobinemia - with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed for alkyl analogues of PAPP (aminophenones 1-20; compound 6 metHb% = 74.1 ± 2). Besides lipophilicity, this structural sub-class suggested there were certain structural requirements for activity, with both branched (10-16) and cyclic (17-20) alkyl analogues exhibiting inferior in vitro metHb induction. Of the four candidates (compounds 4, 6, 13 and 23) evaluated in vivo, 4 exhibited the greatest toxicity. In parallel, aminophenone bioisosteres, including oximes 30-32, sulfoxide 33, sulfone 34 and sulfonamides 35-36, were found to be inferior metHb inducers to lead ketone 4. Closer examination of Hammett substituent constants suggests that a particular combination of the field and resonance parameters may be significant with respect to the redox mechanisms behind PAPPs metHb toxicity.

Fused pyridine derivatives

The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.